Clinical trial
Phase 2 Trial of Bevacizumab in Combination With Pemetrexed
NCT00227019 · Heather Wakelee, Other · Completed
Key facts
| NCT number | NCT00227019 |
|---|---|
| Title | Phase 2 Trial of Bevacizumab in Combination With Pemetrexed |
| Official title | Phase II Trial of Bevacizumab in Combination With Pemetrexed as Second Line Therapy in Patients With Stable Brain Metastases From Non-small Cell Lung Cancer (NSCLC) (Excluding Squamous Cell Carcinoma) |
| Lead sponsor | Heather Wakelee, Other |
| Collaborators | Eli Lilly and Company Industry Genentech, Inc. |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-small Cell Lung Cancer (NSCLC), Lung Cancer, Neoplasm Metastasis |
| Intervention type | Drug |
| Interventions | Bevacizumab, Pemetrexed, Vitamin B12, Folate, Dexamethasone |
| Enrollment | 16 |
| Start date | Mar 1, 2006 |
| Primary completion | Nov 1, 2010 |
| Completion | Dec 1, 2016 |
| First posted | Sep 27, 2005 |
| Last update posted | Mar 6, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: